Shawn Xiao
Co-Founder & Chief Product Officer Synthgene Biotechnology
Seminars
Wednesday 28th January 2026
Challenges & Solutions for in Vivo CAR-T Therapy
11:30 am
- Explore how mRNA-based in vivo CAR-T therapy is a promising new area but faces significant challenges in targeted delivery and manufacturing
- Discover LNP design, optimal antibody screening/conjugation, comprehensive analytical methods, and navigating IP and GMP manufacturing requirements
- Discover how Synthgene Biotech has built an integrated platform for modern clinical applications. The platform is designed to overcome the core barriers and accelerate the development of clinically viable in vivo CAR-T therapies
